Combined Multimarker Screening and Randomized Patient Treatment with Aspirin for Evidence-Based Preeclampsia Prevention (ASPRE)
Source: View publication →
In pregnant women identified as high-risk for preterm preeclampsia via a first-trimester screening algorithm, initiation of 150 mg of aspirin daily from 11–14 weeks until 36 weeks of gestation significantly reduced the incidence of preterm preeclampsia compared to placebo.
Key Findings
Study Design
Study Limitations
Clinical Significance
The ASPRE trial provides robust evidence for the efficacy of low-dose aspirin in high-risk pregnancies, specifically for the prevention of preterm preeclampsia. It supports the paradigm shift toward integrating first-trimester screening—combining maternal history, biochemical markers, and doppler ultrasound—to identify women who will benefit most from prophylactic aspirin therapy initiated before 16 weeks of gestation.
Historical Context
For decades, the benefit of low-dose aspirin for preeclampsia prevention was limited by heterogeneous trial results and confusion regarding optimal timing, dosing, and patient selection. Early meta-analyses showed modest benefits, but the ASPRE trial was instrumental in clarifying that the efficacy of aspirin is optimized when initiated early (first trimester) and at a sufficient daily dose (150 mg), specifically targeting the reduction of preterm preeclampsia.
Guided Discussion
High-yield insights from every perspective
What is the biological rationale for initiating low-dose aspirin specifically before 16 weeks of gestation in patients at high risk for preeclampsia, and how does aspirin's mechanism of action address the underlying pathophysiology?
Key Response
Preeclampsia is fundamentally a disorder of defective deep placentation. During the first half of pregnancy, trophoblasts remodel maternal spiral arteries into high-capacitance vessels. Aspirin is thought to prevent preeclampsia by inhibiting the production of thromboxane A2 (a vasoconstrictor and platelet aggregator) more than prostacyclin (a vasodilator). Initiating aspirin before 16 weeks targets the window of trophoblast invasion; once spiral artery remodeling is complete or failed, the drug's ability to alter the placental architecture and prevent early-onset disease is significantly diminished.
The ASPRE trial utilized a multimarker screening algorithm rather than the clinical risk factor approach (e.g., history of hypertension, nulliparity) recommended by ACOG or USPSTF. Compare the sensitivity and false-positive rates of the ASPRE algorithm to traditional history-based screening for preterm preeclampsia.
Key Response
Traditional screening based on maternal history (USPSTF/ACOG) typically has a detection rate for preterm preeclampsia of approximately 40-50% with a 10% false-positive rate. In contrast, the ASPRE multimarker algorithm—which combines maternal factors, mean arterial pressure, uterine-artery pulsatility index, and placental growth factor (PlGF)—achieved a detection rate of approximately 77% for preterm preeclampsia at the same false-positive rate. This suggests that multimarker screening is significantly more effective at identifying the specific cohort that benefits most from aspirin prophylaxis.
ASPRE demonstrated a 62% reduction in preterm preeclampsia (<37 weeks) but no significant reduction in term preeclampsia (≥37 weeks). What does this disparity suggest regarding the 'two-stage' model of preeclampsia and the limitations of aspirin therapy?
Key Response
This finding supports the hypothesis that 'early-onset' (preterm) and 'late-onset' (term) preeclampsia have distinct etiologies. Preterm preeclampsia is primarily driven by placental insufficiency and failure of spiral artery remodeling (the placental stage), which is responsive to aspirin's effect on vascular development. In contrast, term preeclampsia is often driven by maternal constitutional factors, such as metabolic syndrome or cardiovascular maladaptation (the maternal stage), where the initial placental trigger is less dominant, rendering aspirin prophylaxis less effective.
The ASPRE trial employed a dose of 150 mg of aspirin administered at bedtime. Given that the standard of care in the United States has historically been 81 mg, what evidence-based arguments support transitioning to a higher, nocturnal dose for high-risk patients?
Key Response
Evidence suggests a dose-response relationship for aspirin in pregnancy, with some patients exhibiting 'aspirin resistance' at 81 mg due to increased blood volume and faster clearance. The 150 mg dose used in ASPRE showed superior efficacy in preventing preterm preeclampsia without increasing bleeding risks. Furthermore, nocturnal administration is theorized to be more effective because the peak effect coincides with the morning surge of the renin-angiotensin-aldosterone system and thromboxane production, potentially providing better blood pressure regulation.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
The ASPRE trial utilized a 'competing risks' model for preeclampsia screening rather than a traditional logistic regression for a binary outcome. Explain the statistical advantage of this approach in the context of varying gestational ages at delivery.
Key Response
The competing risks model treats preeclampsia as a continuous distribution of the gestational age at which a patient would develop the disease if they were not delivered for other reasons. Traditional binary models (PE vs. no PE) ignore the timing of onset. By modeling the 'time-to-preeclampsia,' the ASPRE algorithm allows for a personalized risk assessment that accounts for the fact that every pregnancy would eventually develop preeclampsia if it continued long enough; this increases the precision of predicting specifically the 'early-onset' phenotype which carries the highest morbidity.
Despite the impressive reduction in preterm preeclampsia, the ASPRE trial required screening over 26,000 women to randomize approximately 1,800. What are the primary threats to the external validity and feasibility of this intervention in a standard community obstetric setting?
Key Response
A critical reviewer would flag the 'pragmatic implementation' gap. The trial relied on highly standardized uterine-artery Doppler measurements and PlGF assays, which are not routinely available or quality-controlled in most community settings. The screening-to-enrollment ratio highlights that the efficacy of the treatment is contingent upon a sophisticated, high-cost screening infrastructure. Without access to these specific biomarkers and sonographic expertise, the generalizability of the 62% risk reduction to the general population using clinical history alone is questionable.
The USPSTF currently recommends 81 mg of aspirin for women with one or more high-risk factors. Based on ASPRE, should guidelines move toward universal multimarker screening and a 150 mg dose, or are there significant barriers to this update?
Key Response
While ASPRE provides Level 1 evidence for the 150 mg dose and multimarker screening, several barriers prevent immediate universal adoption. Current ACOG and USPSTF guidelines emphasize low-cost, accessible history-based screening. Updating to the ASPRE protocol would require a paradigm shift in laboratory and ultrasound utilization. However, most experts now agree that if a patient is identified as high-risk by the ASPRE criteria, the 150 mg dose is likely superior to 81 mg, leading some societies (like FIGO) to adopt the higher dose while others remain cautious about the cost-effectiveness of the screening itself.
Clinical Landscape
Noteworthy Related Trials
CLASP Trial
Tested
Low-dose aspirin (60 mg/day)
Population
Pregnant women at high risk for preeclampsia
Comparator
Placebo
Endpoint
Proteinuric preeclampsia
EPIPP Trial
Tested
Low-dose aspirin (60 mg/day)
Population
Nulliparous women at risk for preeclampsia
Comparator
Placebo
Endpoint
Preeclampsia occurrence
Paris Collaborative Group Trial
Tested
Low-dose aspirin (75-150 mg/day)
Population
Pregnant women at risk of preeclampsia
Comparator
Placebo
Endpoint
Incidence of preeclampsia
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis